Kidney involvement in hemoblastosis


DOI: https://dx.doi.org/10.18565/therapy.2019.2.117-122

Makhina V.I., Voloshinova E.V., Golubinov F.D.

1) FSBEI HE «V.I. Razumovskiy Saratov State Medical University» of the Ministry of Healthcare of Russia; 2) State Health Care Institution Regional Clinical Hospital, Saratov
Hematological malignancies – a group of tumor diseases arising from hematopoietic cells and affecting many organs. The frequency and variants of kidney damage differ in malignant diseases of lymphoid and myeloid tissue. The given clinical observations describe the difficulties of diagnosis and treatment of nephropathies in case of primary myelofibrosis and light chains disease. Membranoproliferative glomerular profile in the debut of hematological diseases is described. Modern clinical and pathogenetic features of these diseases, efficiency of the developed methods of treatment are discussed.

Literature



  1. Гематология: национальное руководство. Под ред. О.А. Рукавицына. М., 2015. 776 с.

  2. Arber D.A., Orazi A., Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391–405.

  3. Меликян А.Л., Туркина А.Г., Абдулкадыров К.М., Зарицкий А.Ю., Афанасьев Б.В., Шуваев В.А., Ломаиа Е.Г., Морозова Е.В., Байков В.В., Голенков А.К., Суборцева И.Н., Соколова М.А., Ковригина А.М., Мартынкевич И.С., Грицаев С.В., Судариков А.Б., Суханова Г.А., Иванова В.Л., Капланов К.Д., Константинова Т.С., Поспелова Т.И., Агеева Т.А., Шатохин Ю.В., Савченко В.Г. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз). Гематология и трансфузиология. 2014; 4: 31–57.

  4. Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., Them N.C.C. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 2013; 369(25): 2379–90.

  5. Said S.M., Leung N., Sethi S., Cornell L.D., Fidler M.E., Grande J.P., Herrmann S., Tefferi A., D’Agati V.D., Nasr S.H. Myeloproliferative neoplasms cause glomerulopathy. Kidney International. 2011; 80: 753–59. https://doi.org/10.1038/ki.2011.147.

  6. Захарова Е.В., Столяревич Е.С., Виноградова О.В., Тареева А.Б., Макарова Т.А., Михайлова Н.А., Ипатьева Е.И.,Тареева Е.И., Шубина А.В., Бисикало М.Л., Трапезина И.И. Поражения почек при лимфоплазмацитарных заболеваниях (обзор литературы и клинические наблюдения). Нефрология и диализ. 2014; 11(2): 68–93.

  7. Pant A.D., Solez K. Light chain deposition disease in kidney: a review of the literature. J. Pathol. Nepal. 2011; 1: 56–59.

  8. Rajasekaran A., Ngo T.T., Abdelrahim M., Glass W., Podoll A., Verstovsek S., Abudayyeh A. Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. BMC. Nephrol. 2015; 16: 121.

  9. Del Sordo R., Brugnano R., Covarelli C., Fiorucci G., Falzetti F., Barbatelli G., Nunzi E., Sidoni A. Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era. Clin. Nephrol. Case Stud. 2017; 5: 70–77.

  10. Виноградова О.Ю., Шуваев В.А., Мартынкевич И.С., Панкрашкина М.М., Фоминых М.С., Ефремова Е.В., Крутикова К.Ю., Полушкина Л.Б., Шаркунов Н.Н., Волошин С.В., Чечеткин А.В. Таргетная терапия миелофиброза. Клиническая онкогематология. 2017; 10(4): 471–478.

  11. Verstovsek S., Mesa R.A., Gotlib J. et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J. Hematol. Oncol. 2017; 10(1): 55.

  12. Tefferi A., Guglielmelli P., Pardanani A., Vannucchi A.M. Myelofibrosis treatment Algorithm 2018. Blood Cancer J. 2018; 8(8): 72.

  13. Gianelli U., Vener C., Bossi A. et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod. Pathol. 2012; 25: 1193–202.

  14. Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2016; 91: 1262–71.

  15. Kaygusuz I., Koc M., Arikan H. et al. Focal segmental glomerulosclerosis associated with idiopathic myelofibrosis. Ren. Fail. 2010; 32: 273–76.

  16. Jimenez-Zepeda V.H. Light chain deposition disease: novel biological insights and treatment advances. Int. J. Lab. Hematol. 2012; 34: 347–55.

  17. Telio D., Shepherd J., Forrest D. et al. High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease. Bone Marrow Transplant. 2012; 47: 453–55.

  18. Toshiharu Ueno, Koichi Kikuchi, Ryo Hazue, Koki Mise, Keiichi Sumida, Noriko Hayami, Tatsuya Suwabe, Junichi Hoshino, Naoki Sawa, Kenji Arizono, Shigeko Hara, Kenmei Takaichi, Takeshi Fujii,Kenichi Ohashi, Yoshifumi Ubara. Five sequential evaluations of renal histology in a patient with light chain deposition disease. Intern. Med. 2016; 55(20): 2993–99.

  19. Рехтина И.Г., Бирюкова Л.С. Болезнь отложения легких цепей. В кн.: Н.А. Мухина, гл. ред. Нефрология. Национальное руководство. Краткое издание. М., 2014. С. 394–397.


About the Autors


Elena V. Voloshinova, PhD, associate professor of the Department of hospital therapy of general medicine faculty of V.I. Razumovsky Saratov state medical university of the Ministry of Healthcare of Russia. Address: 410012, Saratov, 112 B. Kazachya St. Tel.: +7 (8452) 49-14-37. E-mail: voloshinovaelena@mail.ru
Violetta I. Makhina, post-graduate student of the Department of hospital therapy of general medicine faculty of V.I. Razumovsky Saratov state medical university of the Ministry of Healthcare of Russia. Address: 410012, Saratov, 112 B. Kazachya St. Tel.: +7 (8452) 49-14-37. E-mail: violettamakhina@mail.ru
Philipp D. Golubinov, head of the nephrology Department of the Regional clinical hospital state healthcare institution. Address: 410053, Saratov, 1 Smirnovskoe ushelje St. Tel.: +7 (8452) 49-14-59. E-mail: golubinov@yandex.ru


Бионика Медиа